EF Hutton Reiterates Buy on Allogene Therapeutics, Maintains $15 Price Target
Portfolio Pulse from richadhand@benzinga.com
EF Hutton analyst Tony Butler reiterates a Buy rating on Allogene Therapeutics (NASDAQ:ALLO) and maintains a $15 price target.
May 26, 2023 | 10:17 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton analyst Tony Butler reiterates a Buy rating on Allogene Therapeutics and maintains a $15 price target.
The reiterated Buy rating and maintained $15 price target by EF Hutton analyst Tony Butler indicates a positive outlook for Allogene Therapeutics. This news is likely to have a positive impact on the stock price in the short term as it shows confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100